Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

LOS ANGELES, CA / ACCESSWIRE / July 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DXCM Investors Can Join The DexCom Inc Securities Fraud Investigation With The Schall Law Firm

Edwards Lifesciences

BiomX Inc.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `

Top 3 Health Care Stocks That May Explode In Q3

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

DexCom, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - DXCM

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTOR ALERT: DexCom, Inc. is being Investigated for Securities Fraud by BFA Law; Investors that Suffered Losses are Notified to Contact the Firm (NASDAQ:DXCM)

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

DexCom, Inc. (DXCM) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

DXCM ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your DexCom, Inc. investment

NEW YORK CITY, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM). Investors who purchased DexCom securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DXCM.

DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into DexCom, Inc. and Encourages Investors to Contact the Firm!

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) (“DexCom”). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that.

NASDAQ: DXCM Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (NASDAQ: DXCM) Investors with Significant Losses to Contact the Firm

Lost Money on DexCom, Inc. (DXCM)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DXCM Investors Can Participate In The DexCom, Inc. Securities Fraud Investigation With The Schall Law Firm

Shareholder Rights Advocates at Levi & Korsinsky Investigate DexCom, Inc. (DXCM) Regarding Possible Securities Fraud Violations

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM FRAUD INVESTIGATION: DexCom, Inc. (NASDAQ:DXCM) is being Investigated for Securities Fraud by BFA Law; Shareholders with Losses are Alerted to Contact the Firm

DexCom stock crashed after the company reported disappointing Q2 results and cut its full-year guidance. This performance raised questions about the potential impact of GLP-1 drugs on DexCom's business.

DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DXCM Investors Can Join The DexCom, Inc. Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

DXCM ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders Who Lost Money

SAN DIEGO , July 29, 2024 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether DexCom, Inc. (NASDAQ: DXCM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.

Johnson Fistel Begins Investigation into DexCom Following a Significant Drop in the Company's Stock

Tandem Diabetes Care

MARKHAM, Ontario--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM) today announced the updated t:slim X2™ insulin pump software is compatible with both Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems and is authorized for sale by Health Canada. This integration allows users of the t:slim X2 insulin pump with Control-IQ technology, the #1 rated automated insulin delivery (AID) system in Canada,* to have even more choice in how they ma.

Tandem Diabetes Care and Dexcom Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada

Super Micro Computer

Walgreens

You don't have to wait any longer for a great crash to arrive. Some S&P 500 stocks are already in a world of hurt.

Worried About A Looming 40% Crash? It's Here Already For 12 Stocks

NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTIGATION NEWS: DexCom, Inc. (NASDAQ:DXCM) is being Investigated for Securities Fraud by BFA Law; Investors with Losses are Notified to Contact the Firm

Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device.

Is Beaten-Down Dexcom Stock a Buy on the Dip?

NEWTOWN, Pa. , July 28, 2024 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Dexcom, Inc. (NASDAQ: DXCM) resulting from allegations of providing potentially misleading business information to the investing public.

Edelson Lechtzin LLP Announces Investigation Dexcom, Inc. (NASDAQ: DXCM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

monday.com

Both companies have favorable financials and unique value propositions for consumers in their markets. DexCom is capitalizing on the ways that its devices can help patients in virtually all stages of diabetes.

2 Magnificent Growth Stocks to Buy Right Now

NEW YORK, NY / ACCESSWIRE / July 27, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTIGATION ANNOUNCED: BFA Law Announces that it is Investigating DexCom, Inc. (NASDAQ:DXCM) for Securities Fraud on behalf of Shareholders who Lost Money

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on behalf of DexCom stockholders. Our investigation concerns whether DexCom has violated the federal securities laws and/or engaged in other unlawful business practices.

DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of DexCom Stockholders and Encourages Investors to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving DexCom, Inc. (NASDAQ: DXCM) focused on whether DexCom and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in this investigation or if you are a DexCom investor who suffered a loss and would like to learn more, you can provide you.

DXCM INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into DexCom, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

News for DexCom Stock (DXCM)